Global Green, Inc. Announces Trial Studies Indicate Use of Salmogenics May Improve Performance of Broilers

TALLAHASSEE, Fla., Dec. 19, 2012 /PRNewswire/ -- Global Green, Inc. (OTCBB:GOGC) announced today that continuing internal field trial studies show that the use of Salmogenics, the Company's patented Salmonella Vaccine, may increase the performance of broilers, resulting in a healthier protein source and leading to increased profit for the poultry grower.

Comparing the experimental or vaccinated broilers over the controls, the studies indicated:

• Improved broiler performance included an average of a .126 pound weight gain, with each bird weighing an average of 5.73 pounds
• Feed conversion improvement of 0.039%
• Mean mortality dropped to 1.406% as compared to the 3.281%, representing a 57% improvement

"As we were preparing for our 2012 World Animal Health Congress presentation, we reviewed all of our data, including a 1996 internal study by our Chief Scientist, Konky Sotomayor, DVM. We decided to disclose previously unannounced benefits of Salmogenics," stated Dr. Mehran Ghazvini, Chairman and CEO.

Research shows that while Salmogenics can reduce the levels of fecal Salmonella when injected in-ovo (in the egg) in broilers, it also suggests that performance may have improved to levels of statistical value in these chickens.

The 1996 49-day trial study was conducted on 5,120 Ross chickens injected in-ovo at 17 days of embryonic stage and kept in raised wire pens of 5 x 10 feet at a 0.82 ft²/bird density.  The studies indicate improved broiler performance compared to controls when broilers are reared in relatively clean, non-stress conditions settings of battery cages, enough to warrant further research to sustain performance claims, with a feed conversion rate of .039%.  Further studies will be conducted to determine the levels of enhancement that Salmogenics could produce in injected broilers.

If you assume that all of the 40 billion broiler chickens in the world are injected with Salmogenics, then the following benefits can be calculated.   

Weight

Poultry production is projected to rise the most among the meats over the next decade, as poultry is the most efficient feed-to-meat converter.  Demand for poultry also remains strong because of its lower cost relative to beef and pork. Improved broiler performance indicates an average of a .126 pounds weight gain, with each bird weighing an average of 5.73 pounds at the end of 49 days.

Citing USDA composite prices based on whole carcass weight, the National Chicken Council reported earlier that, price per pound, from 2002 to 2012:

• Wholesale prices have increased from 53 cents to 93 cents
• Retail prices have increased from $1.07 to $1.33

The .126 pound weight gain per bird, as reported in the study, would have an increased yield to the poultry industry and to the consumer.  (.126 pounds x 40 billion estimated chickens worldwide = 5,040,000,000 pounds x 93 cents per pound = $4,687,200,000 additional revenue to the poultry industry worldwide, or $1,171,800,000 in the U.S. alone.)

Mortality

Our study indicates mortality rate dropping from 3.281% to 1.406% with the use of Salmogenics, a 57% improvement.

If Salmogenics were to be used on the estimated 40 billion chickens worldwide, 750,000,000 (40 billion x 3.281% lost chickens to the industry because of no injections = 1,312,400,000; if vaccinated with Salmogenics, 40 billion x 1.406% = 562,400,000 lost chickens to industry; 1,312,400,000 – 562,400,000 = 750,000,000) additional chickens would be saved due to the reduction in mortality.  Multiplying this number by the 5.73 pounds of weight per bird as indicated by our study equals 4,297,500,000 more pounds of chicken available on the market.  This additional available chicken equates to $3,996,675,000, based on USDA-cited wholesale prices.  Added to the $4,687,200,000, as outlined in the previous paragraph, this total increases to a potential $8,683,875,000 additional revenue to the poultry industry.

"We are excited about the preliminary results of the trial studies.  When extrapolating the weight gain with Salmogenics-vaccinated broilers, the reduced mortality of the bird, and the ever-increasing cost of chicken to the consumer, the potential of the Salmogenics vaccine on the poultry industry would have far-reaching impact," Dr. Ghazvini concluded.

The Salmogenics vaccine is in its last stages of testing and trials before the final United States Department of Agriculture/Food Safety and Inspection Service ("USDA") approval for its commercial application.

Global Green, Inc. is a green pharmaceutical company committed to identifying technology platforms and commercializing products that contain natural organisms that are not genetically modified, utilizing pharmaceutical standards.  Salmogenics, the Company's flagship product, was developed by Nutritional Health Institute Laboratories, LLC, research affiliate and majority shareholder.  The vaccine is currently in the final stage of the USDA approval process. For more information, visit www.globalgreeninc.org.

Forward-Looking Statement
This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Investors are cautioned that such forward-looking statements involve risks and uncertainties, which include among others, the inherent uncertainties associated with smaller reporting companies, including without limitation, other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

Contact: 
Pam Lagano  
[email protected]  
727.480.3082  

SOURCE Global Green, Inc.